Erdogan S, Ergin M, Tuncer I
Department of Pathology, School of Medicine; Cukurova University, 1330 Adana, Turkey.
Neoplasma. 2003;50(5):326-30.
The c-erbB-2 gene codes for a membrane receptor protein that is homologous to the epidermal growth factor receptor. Differential polymerase chain reaction (PCR) is an alternative semi-quantitative method for evaluating gene amplification and can be performed in formalin-fixed paraffin-embedded specimens. We aimed to compare differential PCR and IHC (immunohistochemistry) in the determination of c-erbB-2 status of breast cancers. Correlation between the prognostic impact of c-erbB-2 gene amplification and protein overexpression with conventional prognostic factors were also evaluated. Differential PCR and IHC for c-erbB-2 were performed on formalin-fixed paraffin sections of 60 invasive breast cancers. Results and the relation with the other prognostic parameters were compared. A highly significant degree of concordance between differential PCR and IHC in the evaluation of c-erbB-2 status of breast carcinoma was detected. Amplification and overexpression were significantly related to the number of metastatic lymph nodes, histologic grade, and lymphatic invasion but not age, histologic type, tumor size and estrogen status. We demonstrated and confirmed the importance of c-erbB-2 overexpression and amplification as a single and combined prognostic parameter together with conventional factors and confirmed that it can be detected by both immunohistochemistry and differential PCR techniques in breast carcinoma. This semi-quantitative technique provides reliable results and can be used routinely.
c-erbB-2基因编码一种与表皮生长因子受体同源的膜受体蛋白。差异聚合酶链反应(PCR)是评估基因扩增的另一种半定量方法,可在福尔马林固定石蜡包埋标本中进行。我们旨在比较差异PCR和免疫组织化学(IHC)在确定乳腺癌c-erbB-2状态方面的效果。还评估了c-erbB-2基因扩增和蛋白过表达的预后影响与传统预后因素之间的相关性。对60例浸润性乳腺癌的福尔马林固定石蜡切片进行c-erbB-2的差异PCR和IHC检测。比较结果及其与其他预后参数的关系。在评估乳腺癌c-erbB-2状态时,检测到差异PCR和IHC之间具有高度显著的一致性。扩增和过表达与转移淋巴结数量、组织学分级和淋巴浸润显著相关,但与年龄、组织学类型、肿瘤大小和雌激素状态无关。我们证明并确认了c-erbB-2过表达和扩增作为单一及与传统因素联合的预后参数的重要性,并证实其可通过免疫组织化学和差异PCR技术在乳腺癌中检测到。这种半定量技术提供可靠结果,可常规使用。